These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37732873)

  • 1. Bilastine 0.6% preservative-free eye drops, an effective once-daily treatment to reduce signs and symptoms of allergic conjunctivitis: A pooled analysis of two randomized clinical trials.
    Gomes PJ; Ciolino JB; Arranz P; Gonzalo A; Fernández N; Hernández G
    J Investig Allergol Clin Immunol; 2023 Sep; ():0. PubMed ID: 37732873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis.
    Gomes PJ; Ciolino JB; Arranz P; Hernández G; Fernández N
    J Investig Allergol Clin Immunol; 2024 Jun; 34(3):167-176. PubMed ID: 36811846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study.
    Gomes PJ; Ciolino JB; Arranz P; Hernández G; Fernández N
    J Investig Allergol Clin Immunol; 2023 Jul; 33(4):271-280. PubMed ID: 35234641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.
    Torkildsen GL; Abelson MB; Gomes PJ
    Clin Ther; 2008 Jul; 30(7):1272-82. PubMed ID: 18691986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model.
    Meier EJ; Torkildsen GL; Gomes PJ; Jasek MC
    Clin Ophthalmol; 2018; 12():2617-2628. PubMed ID: 30587908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL; Abelson MB; Ober A; Gotnes PJ
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.
    D'Arienzo PA; Leonardi A; Bensch G
    Clin Ther; 2002 Mar; 24(3):409-16. PubMed ID: 11952024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study.
    Kuna P; Jutel M; Pulka G; Tokarski S; Arranz P; Hernández G; Fernández Hernando N
    Clin Ophthalmol; 2023; 17():735-746. PubMed ID: 36909350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
    Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM
    Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis.
    Greiner JV; Mundorf T; Dubiner H; Lonsdale J; Casey R; Parver L; Kapik BM; Shams NB; Abelson MB
    Am J Ophthalmol; 2003 Dec; 136(6):1097-105. PubMed ID: 14644221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
    Greiner JV; Minno G
    Clin Ther; 2003 Jul; 25(7):1988-2005. PubMed ID: 12946546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular Biodistribution of Once-Daily 0.6% Bilastine Eye Drops Reveals Highest Levels in Conjunctiva Up to 24 h Postadministration.
    Torrens I; Ganza Á; Hernández G; Gonzalo A; Zazpe A
    J Ocul Pharmacol Ther; 2022 Nov; 38(9):617-625. PubMed ID: 36269652
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation.
    Ochoa D; Román M; Belmonte C; Martín-Vilchez S; Mejía-Abril G; Abad-Santos F; Hernández G; Arranz P; Elgezabal L; Fernández N
    Adv Ther; 2021 Jul; 38(7):4070-4081. PubMed ID: 34125400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
    Abelson MB; Gomes PJ; Pasquine T; Edwards MR; Gross RD; Robertson SM
    Allergy Asthma Proc; 2007; 28(4):427-33. PubMed ID: 17883910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
    McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G
    Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB; Lanier RQ
    Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model.
    Torkildsen G; Narvekar A; Bergmann M
    Clin Ophthalmol; 2015; 9():1703-13. PubMed ID: 26392751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.